|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOP10 |
Gene summary for NOP10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOP10 | Gene ID | 55505 |
| Gene name | NOP10 ribonucleoprotein | |
| Gene Alias | DKCB1 | |
| Cytomap | 15q14 | |
| Gene Type | protein-coding | GO ID | GO:0000154 | UniProtAcc | Q9NPE3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55505 | NOP10 | CA_HPV_1 | Human | Cervix | CC | 1.82e-06 | 7.57e-04 | 0.0264 |
| 55505 | NOP10 | CA_HPV_3 | Human | Cervix | CC | 1.47e-04 | -1.66e-01 | 0.0414 |
| 55505 | NOP10 | CCI_1 | Human | Cervix | CC | 1.34e-12 | -7.89e-01 | 0.528 |
| 55505 | NOP10 | CCI_2 | Human | Cervix | CC | 3.92e-04 | -5.28e-01 | 0.5249 |
| 55505 | NOP10 | CCI_3 | Human | Cervix | CC | 1.39e-14 | -7.62e-01 | 0.516 |
| 55505 | NOP10 | CCII_1 | Human | Cervix | CC | 3.70e-24 | -7.98e-01 | 0.3249 |
| 55505 | NOP10 | Tumor | Human | Cervix | CC | 9.26e-08 | 3.88e-01 | 0.1241 |
| 55505 | NOP10 | sample3 | Human | Cervix | CC | 2.47e-07 | 3.26e-01 | 0.1387 |
| 55505 | NOP10 | H2 | Human | Cervix | HSIL_HPV | 3.68e-06 | -3.72e-01 | 0.0632 |
| 55505 | NOP10 | L1 | Human | Cervix | CC | 4.97e-04 | -1.20e-01 | 0.0802 |
| 55505 | NOP10 | T3 | Human | Cervix | CC | 1.48e-08 | 3.24e-01 | 0.1389 |
| 55505 | NOP10 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.03e-02 | 1.65e-01 | 0.0155 |
| 55505 | NOP10 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.67e-09 | 5.87e-01 | -0.1808 |
| 55505 | NOP10 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.64e-06 | 4.23e-01 | -0.0811 |
| 55505 | NOP10 | HTA11_78_2000001011 | Human | Colorectum | AD | 4.23e-02 | 9.01e-02 | -0.1088 |
| 55505 | NOP10 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.17e-13 | 4.06e-01 | -0.1954 |
| 55505 | NOP10 | HTA11_411_2000001011 | Human | Colorectum | SER | 2.25e-08 | 8.81e-01 | -0.2602 |
| 55505 | NOP10 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.57e-04 | 3.02e-01 | -0.1207 |
| 55505 | NOP10 | HTA11_83_2000001011 | Human | Colorectum | SER | 4.59e-08 | 4.40e-01 | -0.1526 |
| 55505 | NOP10 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.49e-13 | 4.29e-01 | -0.1464 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006278110 | Thyroid | PTC | RNA-dependent DNA biosynthetic process | 43/5968 | 75/18723 | 4.61e-06 | 5.66e-05 | 43 |
| GO:190487416 | Thyroid | PTC | positive regulation of telomerase RNA localization to Cajal body | 13/5968 | 15/18723 | 1.81e-05 | 1.87e-04 | 13 |
| GO:00322009 | Thyroid | PTC | telomere organization | 74/5968 | 159/18723 | 7.46e-05 | 6.43e-04 | 74 |
| GO:0071897110 | Thyroid | PTC | DNA biosynthetic process | 82/5968 | 180/18723 | 7.98e-05 | 6.81e-04 | 82 |
| GO:002261334 | Thyroid | ATC | ribonucleoprotein complex biogenesis | 292/6293 | 463/18723 | 3.05e-39 | 9.63e-36 | 292 |
| GO:004225434 | Thyroid | ATC | ribosome biogenesis | 203/6293 | 299/18723 | 3.63e-34 | 4.59e-31 | 203 |
| GO:000636432 | Thyroid | ATC | rRNA processing | 157/6293 | 225/18723 | 9.02e-29 | 5.70e-26 | 157 |
| GO:001607232 | Thyroid | ATC | rRNA metabolic process | 161/6293 | 236/18723 | 1.02e-27 | 5.89e-25 | 161 |
| GO:000640326 | Thyroid | ATC | RNA localization | 132/6293 | 201/18723 | 1.13e-20 | 1.93e-18 | 132 |
| GO:003447021 | Thyroid | ATC | ncRNA processing | 216/6293 | 395/18723 | 3.14e-18 | 3.98e-16 | 216 |
| GO:003466021 | Thyroid | ATC | ncRNA metabolic process | 240/6293 | 485/18723 | 2.03e-13 | 9.91e-12 | 240 |
| GO:000072324 | Thyroid | ATC | telomere maintenance | 76/6293 | 131/18723 | 8.21e-09 | 1.75e-07 | 76 |
| GO:000700424 | Thyroid | ATC | telomere maintenance via telomerase | 44/6293 | 69/18723 | 2.84e-07 | 4.29e-06 | 44 |
| GO:007189723 | Thyroid | ATC | DNA biosynthetic process | 91/6293 | 180/18723 | 1.84e-06 | 2.24e-05 | 91 |
| GO:190487221 | Thyroid | ATC | regulation of telomerase RNA localization to Cajal body | 16/6293 | 18/18723 | 1.88e-06 | 2.27e-05 | 16 |
| GO:001083326 | Thyroid | ATC | telomere maintenance via telomere lengthening | 47/6293 | 81/18723 | 5.53e-06 | 5.93e-05 | 47 |
| GO:000627823 | Thyroid | ATC | RNA-dependent DNA biosynthetic process | 44/6293 | 75/18723 | 7.37e-06 | 7.56e-05 | 44 |
| GO:009067021 | Thyroid | ATC | RNA localization to Cajal body | 16/6293 | 19/18723 | 8.15e-06 | 8.27e-05 | 16 |
| GO:009067121 | Thyroid | ATC | telomerase RNA localization to Cajal body | 16/6293 | 19/18723 | 8.15e-06 | 8.27e-05 | 16 |
| GO:009067221 | Thyroid | ATC | telomerase RNA localization | 16/6293 | 19/18723 | 8.15e-06 | 8.27e-05 | 16 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOP10 | SNV | Missense_Mutation | c.24N>G | p.Asn8Lys | p.N8K | Q9NPE3 | protein_coding | tolerated(0.08) | benign(0.158) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| NOP10 | SNV | Missense_Mutation | c.157A>G | p.Lys53Glu | p.K53E | Q9NPE3 | protein_coding | deleterious(0.01) | benign(0.067) | TCGA-DD-AACY-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| NOP10 | SNV | Missense_Mutation | novel | c.12N>T | p.Gln4His | p.Q4H | Q9NPE3 | protein_coding | deleterious(0.04) | benign(0.001) | TCGA-DD-AAW3-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| NOP10 | SNV | Missense_Mutation | novel | c.173A>T | p.Gln58Leu | p.Q58L | Q9NPE3 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NOP10 | SNV | Missense_Mutation | c.152N>C | p.Arg51Pro | p.R51P | Q9NPE3 | protein_coding | deleterious(0.02) | possibly_damaging(0.726) | TCGA-34-5232-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |